China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA) of its biosimilar version of Denmark firm Novo Nordisk’s (NYSE: NVO) Victoza (liraglutide).
Liraglutide: A Crucial Treatment for Diabetes
Liraglutide, an analog of human glucagon-like peptide 1 (GLP-1), is an important target for the treatment of diabetes. It offers a range of physiological functions, including glucose-dependent promotion of insulin secretion, protection of pancreatic islet β-cells, delayed gastric emptying, and decreased appetite, making it a multifaceted therapy for managing blood sugar levels.
Co-Development with Hikma Pharmaceuticals USA, Inc.
Hybio Pharma’s biosimilar version of liraglutide is under co-development with Hikma Pharmaceuticals USA, Inc. in the US. The deal, valued at USD 46.4 million as of the announcement date, signifies a significant step forward in bringing a more accessible alternative to the market for diabetes patients.-Fineline Info & Tech
